Results 151 to 160 of about 60,658 (250)

Oral GLP‐1RA TERN‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies

Obesity, EarlyView.
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey, Julio Rosenstock, Harold E. Bays, Douglas Denham, Anita Kohli, Melanie Haines, Christopher Jones, Ellen Kwan, Erin Castelloe, Tonya Marmon, Emil Kuriakose, Cara Nelson   +11 more
wiley   +1 more source

Immediate allergy against glucagon-like peptide-1 receptor agonist liraglutide. [PDF]

Asia Pac Allergy
Özdemir Ö.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. [PDF]

Vision (Basel)
Lixi F, Troisi M, Calabresi V, Giagoni A, Rossi C, Timofte-Zorila MM, Tarași TC, Vitiello L, Tomi MI, Gheorghe AG, Coco G, Lanzolla G, Giannaccare G.   +12 more
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes. [PDF]

United European Gastroenterol J
Eldesouki MH, Alkasabrah O, Kloub M, Abosheaishaa H, Elfert K, Sharma A, Andrawes S, Duong N.   +7 more
europepmc   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction. [PDF]

ESC Heart Fail
Kassab J, Drazner MH, Thibodeau JT.
europepmc   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source